$HAE

Argus raised its target price for Haemonetics Corp (HAE) to $114.00. The company focuses on medical products for blood and plasma collection, surgical solutions, and hospital transfusion services.

MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.

Haemonetics (HAE) and Twist Bioscience (TWST) shares reached over 5-year highs. HAE rose 2% due to a renewed deal with CSL Plasma, with Citi upgrading it to 'Buy' and raising its target to $123. TWST surged 11% following its AI drug discovery partnership with Eli Lilly's TuneLab, with Leerink raising its target to $160.

Citizens upgraded J.B. Hunt (JBHT) to Outperform with a $300 target, citing a 18% pullback. Goldman upgraded Sunbelt Rentals (SUNB) to Buy with a $93 target, citing strong Q1 results. Macquarie upgraded Trip.com (TCOM) to Outperform with a $53.20 target, citing Q2 earnings. Citi upgraded Haemonetics (HAE) to Buy with a $123 target, citing a supply agreement. BofA upgraded HawkEye 360 (HAWK) to Buy with a $23 target, citing strong growth. Guggenheim downgraded Lyft (LYFT) to Neutral with a $16 ta

Analysts made several calls on Thursday. Goldman upgraded Sunbelt citing growth improvement. Wolfe reiterated Tesla as peer perform. Bernstein downgraded Palo Alto Networks, Okta, and SentinelOne due to valuation. Citizens upgraded JBHT to market outperform. Daiwa reiterated Nvidia as outperform but lowered its price target to $245. RBC initiated Kraft Heinz as outperform. Wells Fargo initiated several bitcoin miners as overweight. Barclays reinstated Paramount Skydance as underweight and Warner

Orchestra BioMed (OBIO) received a $6.1M milestone payment from Haemonetics (HAE) following HAE's acquisition of Vivasure. This adds to a prior $5M upfront payment, with potential for $10M more in earnouts. The funds will support OBIO's AVIM and Virtue SAB clinical trials. HAE's stock closed at $106.31, up 3.53%.

Investing.com's AI strategy exited Haemonetics (HAE) at $103.07, up 89% from its $54.54 entry a year prior. The gain followed a commercial deal with CSL Plasma, a fiscal Q1 beat, and analyst price target increases. Nucor (NUE) also rose 4.2% this week after raising prices and reporting strong earnings.

Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

Haemonetics Corp (HAE) hit a 52-week high of $106.64, up 92.73% over a year. The medical tech firm's stock has surged 72.49% in six months and 14.57% in the past week. Q1 earnings beat estimates, with revenue at $339M. BTIG raised its price target to $96. HAE signed a supply deal with CSL Plasma.